Picture of Bright Minds Biosciences logo

DRUG Bright Minds Biosciences Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m+1.56%
3m+45.68%
6m-29.85%
1yr-48.26%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-69.7%
50d MA+5.01%
200d MA-39.95%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-112.22%
Return on Equity-79.07%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Sep 202430th Sep 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Bright Minds Biosciences EPS forecast chart

Profile Summary

Bright Minds Biosciences Inc. is a biotechnology company. The Company is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy, and pain. It has a portfolio of next generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant depression, post-traumatic stress disorder (PTSD), and pain. Its pipeline includes BMB-101, BMB-202, and BMB-xxx. BMB-101 is for the treatment of Dravet syndrome and other neurological and neuro-psychiatric disorders. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling while avoiding off-target effects.

Directors

Last Annual
September 30th, 2023
Last Interim
December 31st, 2023
Incorporated
May 31st, 2019
Public Since
February 8th, 2021
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ca flag iconCanadian Securities Exchange
Shares in Issue
4,463,837

DRUG Share Price Performance

Upcoming Events for DRUG

Similar to DRUG

Picture of Albert Labs International logo

Albert Labs International

ca flag iconCanadian Securities Exchange

Picture of Algernon Pharmaceuticals logo

Algernon Pharmaceuticals

ca flag iconCanadian Securities Exchange

Picture of Alpha Cognition logo

Alpha Cognition

ca flag iconCanadian Securities Exchange

Picture of Asep Medical Holdings logo

Asep Medical Holdings

ca flag iconCanadian Securities Exchange

Picture of Awakn Life Sciences logo

Awakn Life Sciences

ca flag iconCanadian Securities Exchange

FAQ